Sakue Masuda

Dr. Sakue Masuda

Shonan Kamakura General Hospital, Kamakura, Japan
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2023 in World Journal of Gastroenterology
Verified
Journal Article
Open access
SMSakue Masuda
Sakue Masuda
KKKazuya Koizumi
Kazuya Koizumi
KSKento Shionoya
Kento Shionoya
RJRyuhei Jinushi
Ryuhei Jinushi
MMMakomo Makazu
Makomo Makazu
UHUojima Haruki
Uojima Haruki
Comprehensive review on endoscopic ultrasound-guided tissue acquisition techniques for solid pancreatic tumor

24 October 2021 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
SMSakue Masuda
Sakue Masuda
KKKazuya Koizumi
Kazuya Koizumi
TNTakashi Nishino
Takashi Nishino
TTTomohiko Tazawa
Tomohiko Tazawa
KKKaren Kimura
Karen Kimura
ASAyumu Sugitani
Ayumu Sugitani
Background: Bleeding can be a serious adverse event of endoscopic sphincterotomy (EST). However, the risk of EST bleeding between direct oral anticoagulant (DOAC) users and those who received no antithrombotic agents has not been clarified. This study analyzed the risk factors for bleeding after EST in patients on DOAC and evaluated the Japan Gastroenterological Endoscopy Society (JGES) guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment. Methods: We retrospectively analyzed 524 patients treated with EST who received DOAC or no antithrombotic drug from May 2016 to August 2019. We investigated the risk factors for bleeding. DOAC was typically discontinued for ≤ 1-day based on the JGES guideline. Although DOAC therapy recommenced the next morning after EST in principle, the duration of DOAC cessation and heparin replacement were determined by the attending physician based on each patient’s status. Results: The number of patients on DOAC (DOAC group) and those not on antithrombotic drug (no-drug group) was 42 (8.0%) and 482 (92.0%), respectively. DOAC was discontinued for ≤ 1-day in 17 (40.0%) patients and for > 1-day in 25 (60.0%). Of the 524 patients, 21 (4.0%) had EST bleeding. The bleeding rate was higher in the DOAC group (14.0%) (p = 0.004). Multivariate analysis showed that bleeding occurred more frequently in patients on DOAC (odds ratio [OR] 3.95, 95% confidence interval [CI] 1.37–11.4, p = 0.011), patients with low platelet counts (< 100,000/µl) (OR 6.74, 95% CI 2.1–21.6, p = 0.001), and elderly patients (> 80 years old) (OR 3.36, 95%CI 1.17–9.65, p = 0.024). Conclusions: DOAC treatment, low platelet count, and old age (> 80 years old) are risk factors for EST bleeding. Although the bleeding incidence increased in patients on DOAC who received antithrombotic therapy according to the JGES guidelines, successful hemostasis was achieved with endoscopy in all cases, and no thrombotic events occurred after cessation of DOAC. Thus, the JGES guidelines are acceptable.

Verified
Journal Article
Open access
PDF file
SMSakue Masuda
Sakue Masuda
KKKazuya Koizumi
Kazuya Koizumi
MMMakomo Makazu
Makomo Makazu
HUHaruki Uojima
Haruki Uojima
JKJun Kubota
Jun Kubota
KSKento Shionoya
Kento Shionoya
To prevent the increase of resistant bacteria, it is important to minimize the use of antimicrobial agents. Studies have found that administration for ≤3 days after successful endoscopic retrograde cholangiopancreatography (ERCP) is appropriate. Therefore, the present study aimed to verify if administration of antimicrobial agents can be further shortened to ≤2 days after ERCP. We divided 390 patients with mild and moderate cholangitis who underwent technically successful ERCP from January 2018 to June 2020 and had positive blood or bile cultures into two groups: antibiotic therapy within two days of ERCP (short-course therapy, SCT; n = 59, 15.1%), and for >3 days (long-course therapy, LCT; n = 331, 84.9%). The increased severity after admission and other outcomes were compared between the two groups, and the risk factors for increased severity were verified. There were no between-group differences in patient characteristics. Total length of hospital stay was shorter in SCT than in LCT, and other outcomes in SCT were not significantly different from those in LCT. Being 80 or older was a risk factor for increased severity; however, SCT was not associated with increased severity. Antimicrobial therapy for ≤2 days after successful ERCP is adequate in patients with mild and moderate acute cholangitis.

13 November 2024 in Journal of Hepato-Biliary-Pancreatic Sciences
Verified
Journal Article
Open access
SMSakue Masuda
Sakue Masuda
YIYoshinori Imamura
Yoshinori Imamura
RJRyuhei Jinushi
Ryuhei Jinushi
KKKaren Kimura
Karen Kimura
SRShomei Ryozawa
Shomei Ryozawa
KKKazuya Koizumi
Kazuya Koizumi
Globally, antibiotic resistance is linked to increased morbidity, mortality, and healthcare costs, which necessitates further research on optimal antibiotic usage. Acute cholangitis (AC), a common cause of community‐acquired bacteremia, often requires antimicrobial therapy. Therefore, studying the appropriate use of antibiotics for AC is considered crucial for suppressing the emergence of resistant bacteria and reducing adverse antibiotic‐associated events. The Tokyo Guidelines 2018 (TG18) recommend 4–7 days of antibiotics post‐biliary drainage. However, this lacks strong evidence and is based primarily on various evidence and expert opinions. Recent retrospective studies advocate for a shorter 1–3‐day antibiotic course for AC, thereby prompting a need to reassess the treatment duration to balance therapeutic efficacy and minimize resistance and adverse effects. Choosing the appropriate duration and antibiotics based on susceptibility to pathogens causing cholangitis is important. Awareness of local resistance patterns and understanding patients' risks of resistant pathogens are prerequisite for effective treatment. We must explore the applicability of these guidelines in specific scenarios such as severe AC, positive blood cultures, fever, or hilar biliary obstructions due to malignancy. This comprehensive review considers both the duration and type of antibiotics and aims to enhance treatment outcomes while reducing the risk of resistant bacterial infections.

3 October 2021 in Cureus
Verified
Journal Article
Open access
SMSakue Masuda
Sakue Masuda
KKKazuya Koizumi
Kazuya Koizumi
HUHaruki Uojima
Haruki Uojima
KKKaren Kimura
Karen Kimura
TNTakashi Nishino
Takashi Nishino
ASAkiko Sasaki
Akiko Sasaki
Considering that pathogens resistant to initial antibiotic therapies for cholangitis can affect mortality rates, appropriate initial empiric antibiotic therapy is important. However, evidence regarding the influence of pathogens resistant to initial antibiotics in patients with cholangitis who have undergone early endoscopic retrograde cholangiopancreatography (ERCP) is limited, and the conditions in several cases can improve with early ERCP even when pathogens resistant to initial antibiotics are detected on time. Therefore, this study aimed to assess the influence of pathogens resistant to initial antibiotics on the course of cholangitis in patients undergoing early ERCP. Patients (n=266) with positive blood or bile culture results treated with early ERCP were divided into those with cultures that were resistant to the initial antibiotics (antibiotic-resistant group; n=66; 24.8%) and those with cultures that were sensitive to the initial antibiotics (antibiotic-sensitive group; n=200; 75.2%). The duration of hospitalization, in-hospital mortality rates due to cholangitis, rates of increased disease severity, and complications during hospitalization were studied. Enterococcus, Enterobacter, Citrobacter, and Pseudomonas species showed high resistance to several antibiotics. No significant between-group differences were found in the duration of hospitalization, in-hospital mortality rates due to cholangitis, and rates of increased disease severity. However, the rate of post-ERCP cholecystitis was significantly higher in the antibiotic-resistant group than in the antibiotic-sensitive group (p=0.0245). Even if the initial antibiotics were ineffective, the rate of fatal outcomes did not increase among patients with cholangitis who had undergone early ERCP. However, when initial antibiotics were ineffective, the frequency of post-ERCP cholecystitis increased even after early bile duct decompression.

25 March 2020 in Clinical Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
SMSakue Masuda
Sakue Masuda
KKKazuya Koizumi
Kazuya Koizumi
HUHaruki Uojima
Haruki Uojima
TTTomohiko Tazawa
Tomohiko Tazawa
KKKaren Kimura
Karen Kimura
MKMakoto Kako
Makoto Kako